D. E. Shaw & Co., Inc. Personalis, Inc. Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.17 - $1.65 $16,446 - $23,194	14,057 Added 7.75%	195,352 $228,000
Q1 2024 May 15, 2024	SELL	$1.15 - $2.19 $326,539 - $621,843	-283,947 Reduced 61.03%	181,295 $270,000
Q4 2023 Feb 14, 2024	BUY	$0.93 - $2.35 $73,377 - $185,417	78,901 Added 20.42%	465,242 $977,000
Q3 2023 Nov 14, 2023	SELL	$1.19 - $2.36 $37,271 - $73,917	-31,321 Reduced 7.5%	386,341 $467,000
Q2 2023 Aug 14, 2023	BUY	$1.8 - $3.19 $19,387 - $34,359	10,771 Added 2.65%	417,662 $785,000
Q1 2023 May 15, 2023	SELL	$2.01 - $4.17 $659,806 - $1.37 Million	-328,262 Reduced 44.65%	406,891 $1.12 Million
Q4 2022 Feb 14, 2023	BUY	$1.78 - $3.64 $457,933 - $936,448	257,266 Added 53.83%	735,153 $1.46 Million
Q3 2022 Nov 14, 2022	BUY	$2.89 - $5.32 $394,906 - $726,956	136,646 Added 40.04%	477,887 $1.42 Million
Q2 2022 Aug 15, 2022	BUY	$3.27 - $8.76 $851,390 - $2.28 Million	260,364 Added 321.93%	341,241 $1.18 Million
Q1 2022 May 16, 2022	BUY	$7.56 - $14.3 $611,430 - $1.16 Million	80,877 New	80,877 $662,000

30M

27.5K

85.4K

Ticker PSNL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 45,918,400
Market Cap $237M
Description
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.